Moderna Q1 2026 revenue $389M, GAAP net loss $(1.3)B including $0.9B litigation charge

Moderna, Inc.

2026-Q1 EPS reported -$3.40 revenue$389,000,000

Revenue $389M (+$281M YoY); ~80% from international; GAAP EPS $(3.40) vs $(2.52) YoY.
Net loss $(1.3)B includes $0.9B non-recurring litigation settlement charge; cash $7.5B.
Reaffirms up to 10% revenue growth in 2026; cost of sales guidance ~$1.8B including charge.
EU approved mNEXSPIKE and mCOMBRIAX (flu+COVID combo); Phase 3 initiated for intismeran in NSCLC.
R&D expenses down 24% YoY to $649M; SG&A down 18% to $173M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moderna, Inc. reported first quarter ended March 31, 2026 results: revenue $389 million, net income $(1.3) billion, EPS $(3.40).

Period: first quarter ended March 31, 2026
Revenue: $389 million
Net income: $(1.3) billion
EPS: $(3.40)
Result: reported results

Exact text from the filing

Total revenue for the first quarter of 2026 was $389 million, an increase of $281 million compared to the same period in 2025.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-26-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.